Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 06, 2025, titled "Press Release".
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jagsonpal Pharmaceuticals reported FY25 revenue of ₹2,687 Mn, up 28.8% YoY, with Q4 FY25 revenue at ₹586 Mn (up 34.7% YoY). Operating EBITDA for FY25 grew 59.1% to ₹579 Mn, with margin expanding 410 basis points to 21.5%, driven by the Yash Pharma acquisition integration and disciplined cost management. Business PAT (excluding the exceptional gain from the Faridabad facility sale) rose 66.7% to ₹375 Mn in FY25, while reported PAT stood at ₹554 Mn including the one-time divestment gain. The Board has recommended a 125% dividend (₹2.5 per share), and the company ended the year with a healthy cash balance of ₹1,456 Mn and zero debt. Net working capital cycle was sharply reduced from 59 days in FY22 to 13 days in FY25, and brand Indocap crossed the ₹50 Cr milestone.
Strong double-digit revenue and profit growth, meaningful margin expansion, and a higher dividend payout signal robust operational momentum and shareholder-friendly capital allocation, likely to be viewed positively by the market. The zero-debt balance sheet and improved working capital cycle give the company room to fund further organic and inorganic growth.